Minneapolis-based Urotronic said this week that the FDA approved an investigational device exemption trial for its Optilume drug-coated balloon catheter, which is designed to treat urethral strictures in men.
The 200-patient pivotal trial is slated to start enrolling participants immediately.
Get the full story at our sister site, Drug Delivery Business News.